Market Research Logo

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sarepta Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sarepta Therapeutics, Inc.
  • The report provides overview of Sarepta Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sarepta Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sarepta Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Sarepta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarepta Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarepta Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Sarepta Therapeutics, Inc. Snapshot
Sarepta Therapeutics, Inc. Overview
Key Information
Key Facts
Sarepta Therapeutics, Inc. - Research and Development Overview
Key Therapeutic Areas
Sarepta Therapeutics, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Sarepta Therapeutics, Inc. - Pipeline Products Glance
Sarepta Therapeutics, Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sarepta Therapeutics, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Sarepta Therapeutics, Inc. - Drug Profiles
eteplirsen
Product Description
Mechanism of Action
R&D Progress
SRP-4053
Product Description
Mechanism of Action
R&D Progress
SRP-4045
Product Description
Mechanism of Action
R&D Progress
AVI-7288
Product Description
Mechanism of Action
R&D Progress
radavirsen
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD
Product Description
Mechanism of Action
R&D Progress
PMO-25
Product Description
Mechanism of Action
R&D Progress
SRP-4008
Product Description
Mechanism of Action
R&D Progress
SRP-4044
Product Description
Mechanism of Action
R&D Progress
SRP-4050
Product Description
Mechanism of Action
R&D Progress
SRP-4052
Product Description
Mechanism of Action
R&D Progress
SRP-4055
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Acinetobacter baumannii Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Activate Lamin A for Progeria
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides for Infectious Diseases
Product Description
Mechanism of Action
R&D Progress
Bacterial PPMO
Product Description
Mechanism of Action
R&D Progress
Viral PMO-X
Product Description
Mechanism of Action
R&D Progress
Sarepta Therapeutics, Inc. - Pipeline Analysis
Sarepta Therapeutics, Inc. - Pipeline Products by Target
Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration
Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action
Sarepta Therapeutics, Inc. - Recent Pipeline Updates
Sarepta Therapeutics, Inc. - Dormant Projects
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AVI-4065
AVI-6002
AVI-7537
Sarepta Therapeutics, Inc. - Company Statement
Sarepta Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Sarepta Therapeutics, Inc., Key Information
Sarepta Therapeutics, Inc., Key Facts
Sarepta Therapeutics, Inc. - Pipeline by Indication, 2016
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
Sarepta Therapeutics, Inc. - Pre-Registration, 2016
Sarepta Therapeutics, Inc. - Phase II, 2016
Sarepta Therapeutics, Inc. - Phase I, 2016
Sarepta Therapeutics, Inc. - Preclinical, 2016
Sarepta Therapeutics, Inc. - Discovery, 2016
Sarepta Therapeutics, Inc. - Pipeline by Target, 2016
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2016
Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2016
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2016
Sarepta Therapeutics, Inc., Other Locations
Sarepta Therapeutics, Inc., Subsidiaries
List of Figures
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016
Sarepta Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report